Search results
Showing 6226 to 6240 of 7680 results
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)
This evidence summary has been updated and replaced by NICE guideline NG80.
This evidence summary has been replaced by NICE technology appraisal guidance 336.
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.
This evidence summary has been updated and replaced by NICE guideline NG217.
Induction of labour: misoprostol vaginal delivery system (ESNM38)
We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).
This evidence summary has been updated and replaced by NICE advice ESNM25.
Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)
This evidence summary has been replaced by NICE technology appraisal guidance 486.
Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)
This evidence summary was withdrawn in September 2017 as the medicine is no longer available.
This advice has been updated and replaced by NICE guideline NG221.
Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)
This evidence summary has been updated and replaced by NICE guideline 115.
Significant haemorrhage following trauma: tranexamic acid (ESUOM1)
This evidence summary has been updated and replaced by NICE guideline NG39.
This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.
This evidence summary has been updated and replaced by NICE guideline NG207.